Nancy Simonian, departing Syros Pharmaceuticals CEO
October 2, 2023 11:11 AM EDT
People
R&D

Sy­ros lays off 35% of work­ers, re­places CEO and los­es CSO af­ter axed pacts

Kyle LaHucik

Senior Reporter

Af­ter a decade at the helm, Nan­cy Si­mon­ian will de­part Sy­ros Phar­ma­ceu­ti­cals as the biotech works through a piv­otal can­cer study and ad­justs af­ter los­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times